417 related articles for article (PubMed ID: 22221848)
1. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
2. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
3. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
4. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Metzner HJ; Pipe SW; Weimer T; Schulte S
Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Martinowitz U; Lubetsky A
Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
[TBL] [Abstract][Full Text] [Related]
6. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
Schaub RG
Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
[TBL] [Abstract][Full Text] [Related]
8. Challenges for new haemophilia products from a manufacturer's perspective.
Schulte S
Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
10. Half-life extension through albumin fusion technologies.
Schulte S
Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
[TBL] [Abstract][Full Text] [Related]
11. Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S9-S12. PubMed ID: 27288065
[TBL] [Abstract][Full Text] [Related]
12. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
[TBL] [Abstract][Full Text] [Related]
13. The promise and challenges of bioengineered recombinant clotting factors.
Pipe SW
J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
[TBL] [Abstract][Full Text] [Related]
14. Surgery in haemophilic patients with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
[No Abstract] [Full Text] [Related]
15. Plasma derivatives: new products and new approaches.
Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
[No Abstract] [Full Text] [Related]
19. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
